Free Daily Podcast Summary
Breakpoints: Daily Summaries Delivered
by Society of Infectious Diseases Pharmacists
Get key takeaways, quotes, and insights from Breakpoints in a 5-minute read. Delivered straight to your inbox.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago1h 3m
#134 – ESCMID Global Trials: PETER PEN and ASTARTE
Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Trials Run’ session at ESCMID Global, where two randomized, clinical trials are presented in great depth. This year, both trials focused on treatment of cephalosporin-resistant Enterobacterales bacteremia. Listen to the authors describe why they performed these trials, results, and implications for clinical practice. References: 1. Paul, M., & Rodríguez-Baño, J. (2026, April 20). The trial run: treatment of ESBL bacteraemia[LW1] - off to never-never land. [Presentation]. ESCMID Global 2026, Munich, Germany. ESCMID Global Virtual Platform. 2. Bitterman R, Koppel F, Mussini C, et al. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open. 2021;11(2):e040210. Published 2021 Feb 8. doi:10.1136/bmjopen-2020-040210 3. Marín-Candón A, Rosso-Fernández CM, Bustos de Godoy N, et al. Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial [Internet]. BMJ Open. 2021 Sep 27;11(9):e049481. Available from: bmj.com doi: 10.1136/bmjopen-2021-049481 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, <a href="https://clicktime.symantec.com/3PoPyJU9wVY1CeG5JSoJ5TF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3D-2A2b6F4mrvzRMOPk-2A2ba-2A2bOlEsgbBTfXcxd55wOs9FeTrv
- Apr 17, 202648 min
#133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship
Climate change in the context of healthcare can feel overwhelming but it doesn’t have to be paralyzing. We’re diving into the intersection of climate change and antimicrobial resistance with a focus on practical, actionable steps healthcare organizations can take. Drs. Shreya Doshi, Andrea Pallotta and Preeti Jaggi join Dr. Whitney Buckel to talk about what’s real, what matters for healthcare, and where stewardship teams can make a meaningful impact. References: 1. Sustainabil‑ID. https://sustainabil-id.com/ 2. National Academy of Medicine. Climate Collaborative.https://nam.edu/our-work/programs/climate-and-health/climate-collaborative/ 3. Medicine for a Changing Planet. https://www.medicineforachangingplanet.org 4. Cascades Canada. https://cascadescanada.ca/ 5. EcoRxChoice. https://ecorxchoice.com 6. Rx for Climate. https://www.rxforclimate.org/ 7. Practice Greenhealth. https://practicegreenhealth.org 8. Healthcare Without Harm. https://healthcarewithoutharm.org 9. Healthcare Sustainability and Infectious Diseases. _J Pediatric Infect Dis Soc._https://academic.oup.com/jpids/pages/healthcare-sustainability-and-infectious-diseases 10. PubMed. PMID: 40434281. https://pubmed.ncbi.nlm.nih.gov/40434281/ 11. PubMed Central. PMC12616928. https://pmc.ncbi.nlm.nih.gov/articles/PMC12616928/ 12. Sustainable Healthcare Networks. Scale and spread quality improvement initiative promoting metronidazole IV‑to‑oral switch.https://networks.sustainablehealthcare.org.uk/resources/scale-and-spread-quality-improvement-initiative-promoting-metronidazole-iv-oral-switch- Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, <a href="https://clicktime.symantec.com/3UPSKiX9zWTmFRi5JvbYYuF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTrack
- Mar 13, 20261h 8m
#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy
Episode Notes Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, and what this means for your day‑to‑day antimicrobial decisions. Join us as we dig into the biggest updates, the evidence behind them, and the clinical pearls you won’t want to miss. References: Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024 Nov 4;7(11):e2444495. Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Published July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ Kadry N, Natarajan M, Bein E, Kim P, Farley J. Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections. Clin Infect Dis 2023;76(10:1768-1775. https://academic.oup.com/cid/article/76/10/1768/6980780 USCAST Oral cephalosporin STIC against S. aureus and E. coli meeting recording. https://www.youtube.com/watch?v=HieaVFAC08s MacDougall C. A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram. Clin Infect Dis. 2023;77(11):1501-1503. doi:10.1093/cid/ciad468 Koehl J, Spolsdoff D, Negaard B, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2025;85(3):240-248. doi:10.1016/j.annemergmed.2024.10.013 Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023;76(1):78-88. doi:10.1093/cid/ciac704 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, <a href="https://clicktime.symantec.com/3UPSKiX9zWTmFRi5JvbYYuF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DuVw7WrCV3UsT9jQEoMx19bCJk8wSnOrHKsz-2A2fiDg5jIJz-2A2fPmlAAnjeQMczcZNKe65FwcZB1GSntOoUYpImtNgtdyfUUiYEctoWEc5okmtqjI-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJSsDRBjw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DiSHbkOT6yU9AfKVXVzZYoT6ihqn4rV7u2MtsJu0S4M0%26e%3
- Feb 22, 20261h 0m
#131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines
In this third collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, <a href="https://clicktime.symantec.com/3EzDPdcsg2aGkG24TqSDnQD7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__ur
- Jan 30, 20261h 0m
#130 – Dosing Consult: Amoxicillin
Drs. Ted Morton and Christine Lockowitz join Dr. Ryan Moenster to discuss all things amoxicillin, particularly in our pediatric patients. Our guests answer common questions, such as, what formulations should be used for certain infectious conditions and/or organisms and how to dose amoxicillin to maximize PK/PD optimization without inducing potential adverse events. It is a must-listen for all! This episode also qualifies for 1 hour of BCIDP credit! How to Obtain BCIDP Recertification Credit for this Episode: Visit sidp.org/BCIDP for more information. References: Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010 Nov;29(11):1043-6. doi: 10.1097/INF.0b013e3181f42a53. PMID: 20975453. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. doi: 10.1086/516284. PMID: 9455502. Hakenbeck R, Grebe T, Zähner D, Stock JB. beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol. 1999 Aug;33(4):673-8. doi: 10.1046/j.1365-2958.1999.01521.x. PMID: 10447877. Bax R. Development of a twice daily dosing regimen of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S118-21. doi: 10.1016/j.ijantimicag.2007.09.002. Epub 2007 Nov 5. PMID: 17983732. Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, Sturgeon K, Finn A, Rodriguez-Ruiz JP, Malhotra-Kumar S, Powell C, Faust SN, Alcock AE, Hall D, Robinson G, Hawcutt DB, Lyttle MD, Gibb DM, Sharland M; PERUKI, GAPRUKI, and the CAP-IT Trial Group. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1713-1724. doi: 10.1001/jama.2021.17843. Erratum in: JAMA. 2021 Dec 7;326(21):2208. doi: 10.1001/jama.2021.20219. PMID: 34726708; PMCID: PMC8564579.
- Jan 16, 20261h 22m
#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci
We’re starting 2026 off with a BLAST as Dr. Gregory Eschenauer and Dr. George R Thompson make their Breakpoints debut to discuss Blastomyces, Histoplasma, Coccidioides, and Cryptococcus. They join host Erin McCreary in reviewing epidemiology, diagnostics, clinical presentation, and treatment of these fungal infections. You won’t want to miss this episode!
- Dec 19, 20251h 35m
#128 – IDWeek 2025 Recap
Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top late breaking abstracts, new stewardship data, practice-changing clinical trials, and much more. How to Obtain BCIDP Recertification Credit for this Episode: Visit sidp.org/BCIDP for more information Visit our website! https://breakpoints-sidp.org/
- Nov 28, 202552 min
#127 – What’s Pneu in Community-Acquired Pneumonia Part 2
As promised, our host Dr, Ryan Moenster is back and breaking down the recently published ATS pneumonia guidelines — what’s pneu, what’s controversial, and what it means for your antimicrobial game! Dr. Whitney Hartlage (@whithartlage11) is back to join the conversation, plus fresh takes from Drs. Sharon Weissman and Sahil Angelo (@angelo_sahil). References: Am J Respir Crit Care Med. 2025 Jul 18. doi: 10.1164/rccm.202507-1692ST. Online ahead of print. IDSA Sepsis Task Force. Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clin Infect Dis. 2018 May 2;66(10):1631-1635. doi: 10.1093/cid/cix997. PMID: 29182749; PMCID: PMC6927848.
Get Breakpoints summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Febrile
Sara Dong
ID:IOTS - Infectious Disease Insight Of Two Specialists
Infectious Disease: Insights of Two Specialists
Emerging Infectious Diseases
CENTERS FOR DISEASE CONTROL AND PREVENTION
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
Purple Pen Podcast
Purple Pen Podcast
Decera Clinical Education Infectious Disease Podcast
Decera Clinical Education
Last Week in Medicine
Stephen Jenkins, MD, Austin Rupp, MD
Core IM | Internal Medicine Podcast
Core IM Team
Let's Talk Micro
Luis Plaza
Blood Podcast
American Society of Hematology
The NACE Clinical Highlights Show
NACE
Dermasphere - The Dermatology Podcast
Luke Johnson
About Breakpoints
The SIDP Podcast
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Breakpoints in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Breakpoints daily summary?
It's a free AI-powered email that summarizes new episodes of Breakpoints as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Breakpoints podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Breakpoints product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Society of Infectious Diseases Pharmacists.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
What topics does Breakpoints cover?
Breakpoints covers topics including Science, Education, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Breakpoints summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.